Third-party funding and current grant support

Research of our group mainly relies on third-party funding. Over the last decade in total 6 million Euros could be spent. The table and diagram below show the annually spent funds, separated into funding sources.

Funding / Year	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
DFG	76,862	184,502	121,370	141,476	178,781	196,919	154,190	79,481	79,321	129,750	210,276	232,970
BMBF	118,215	174,212	245,606	46,383					425,146	234,212	182,395	52,559
EU				58,641	134,536	27,203				8,454		252,122
US, NIH						51,280	3,057
Industry	197,260	337,798	175,812	244,143	189,998	164,740	162,885	370,532	131,077	131,324	169,434	136,575
Sum	392,337	696,512	542,788	490,643	503,315	440,142	320,132	450,013	635,544	503,740	562,105	674,226

German Research Foundation (DFG, blue)
German Minister of Science and Research (BMBF, yellow)
European Community (EU, gray)
National Institute of Health (US, green)
Industry fundings (Industry, red)

Recent and Current Funding ID

Funding agency	Title	Funding in Euro
DFG	Structural studies of Shigella-specific Pathogenicity Factors as a Prerequisite for Rational Drug Design	189,750
DFG	Understanding the Binding Characteristics of Aldose Reductase	113,250
DFG	Structure-based Design, Synthesis and Crystallographic Characterisation of Aspartyl protease Inhibitors: Target proteins for HIV- and Malaria-infection	132,550
DFG - FO 806	Cross-correlation of Protein Binding Pockets to detect related Binding Epitopes, unexpected Cross-reactivity and Functional Relationships	216,000
DFG	Interfering with Intracellular Protein-protein Interactions - Probing Protein Functions with Small Molecules, Perturbance of Enzyme Function by Blocking Dimer Interface Formation: Novel Route to Specific Antibiotics	289,100
CCDC	Development of a Scoring Function	28,402
CCDC	Studentship on Cambridge Structural Database – Knowledge-based Hot Spot Analysis	106,812
Bayer Schering	From Targets to Novel Drugs	50,000
Sanofi	Comparison of Binding Pocket using Cavbase to Analyse and Correlate Proteins across Protein Families and Design of Focused Libraries for de novo Design	111,000
Beiersdorf	Design of Inhibitors for humane Tyrosinase by Molecular Modeling and Crystallography	126,000
BMBF	Fragmentscreening "FragScreen" BioChance Plus, New methods for Experimental and Computational Fragment-based Drug Design	910,876
BMBF Zedira	Development of Factor XIIIa - Inhibitors to Prevent Thrombosis	100,000
LOEWE Synmikro	Development of novel bioinformatics methods for the prediction of protein function and interactions. Experimental validation	168,000
ERC AG	Chemogenomic profiling of drug-protein binding by shape, enthalpy/entropy and interaction kinetics	1,754,615
Total		4,296,355